The FDA approved olaparib (Lynparza, AstraZeneca) for the treatment of adults with deleterious or suspected deleterious homologous recombination repair (HRR) gene–mutated metastatic castration-resistant prostate cancer after progression with enzalutamide (Xtandi, Astellas) or abiraterone. Patient selection is based on an FDA-approved companion diagnostic test.
“Prostate cancer has lagged behind other solid tumors in the era of precision medicine. I am thrilled by the approval of